Cecilia Perez Brandan

Dr. Cecilia Perez Brandan

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2010 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ACAdriana M. C. Canavaci
Adriana M. C. Canavaci
JBJuan M. Bustamante
Juan M. Bustamante
APAngel M. Padilla
Angel M. Padilla
Cecilia Perez BrandanCecilia Perez Brandan
Cecilia Perez Brandan
LSLaura J. Simpson
Laura J. Simpson
RTRick L. Tarleton
Rick L. Tarleton
The two available drugs for treatment of T. cruzi infection, nifurtimox and benznidazole (BZ), have potential toxic side effects and variable efficacy, contributing to their low rate of use. With scant economic resources available for antiparasitic drug discovery and development, inexpensive, high-throughput and in vivo assays to screen potential new drugs and existing compound libraries are essential. In this work, we describe the development and validation of improved methods to test anti-T. cruzi compounds in vitro and in vivo using parasite lines expressing the firefly luciferase (luc) or the tandem tomato fluorescent protein (tdTomato). For in vitro assays, the change in fluorescence intensity of tdTomato-expressing lines was measured as an indicator of parasite replication daily for 4 days and this method was used to identify compounds with IC50 lower than that of BZ. This method was highly reproducible and had the added advantage of requiring relatively low numbers of parasites and no additional indicator reagents, enzymatic post-processes or laborious visual counting. In vivo, mice were infected in the footpads with fluorescent or bioluminescent parasites and the signal intensity was measured as a surrogate of parasite load at the site of infection before and after initiation of drug treatment. Importantly, the efficacy of various drugs as determined in this short-term (<2 weeks) assay mirrored that of a 40 day treatment course. These methods should make feasible broader and higher-throughput screening programs needed to identify potential new drugs for the treatment of T. cruzi infection and for their rapid validation in vivo. The treatment of Trypanosoma cruzi infection (the cause of human Chagas disease) remains a significant challenge. Only two drugs, both with substantial toxicity, are available and the efficacy of these dugs is often questioned – in many cases due to the limitations of the methods for assessing efficacy rather than to true lack of efficacy. For these reasons relatively few individuals infected with T. cruzi actually have their infections treated. In this study, we report on innovative methods that will facilitate the discovery of new compounds for the treatment of T. cruzi infection and Chagas disease. Utilizing fluorescent and bioluminescent parasite lines, we have developed in vitro tests that are reproducible and facile and can be scaled for high-throughput screening of large compound libraries. We also validate an in vivo screening test that monitors parasite replication at the site of infection and determines the effectiveness of drug treatment in less than two weeks. More importantly, results in this rapid in vivo test show strong correlations with those obtained in long-term (e.g. 40 day or more) treatment assays. The results of this study remove one of the obstacles for identification of effective and safe compounds to treat Chagas disease.

1 January 2015 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
MMMaría M. Monje-Rumi
María M. Monje-Rumi
Cecilia Perez BrandanCecilia Perez Brandan
Cecilia Perez Brandan
PRPaula G. Ragone
Paula G. Ragone
NTNicolás Tomasini
Nicolás Tomasini
JLJuan Jose Lauthier
Juan Jose Lauthier
PDPatricio Diosque
Patricio Diosque

28 August 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
PDPatricio Diosque
Patricio Diosque
NTNicolás Tomasini
Nicolás Tomasini
JLJuan Jose Lauthier
Juan Jose Lauthier
Louisa Alexandra MessengerLouisa Alexandra Messenger
Louisa Alexandra Messenger
MRMaría Mercedes Monje Rumi
María Mercedes Monje Rumi
MYMatthew Yeo
Matthew Yeo
Trypanosoma cruzi, the aetiological agent of Chagas disease possess extensive genetic diversity. This has led to the development of a plethora of molecular typing methods for the identification of both the known major genetic lineages and for more fine scale characterization of different multilocus genotypes within these major lineages. Whole genome sequencing applied to large sample sizes is not currently viable and multilocus enzyme electrophoresis, the previous gold standard for T. cruzi typing, is laborious and time consuming. In the present work, we present an optimized Multilocus Sequence Typing (MLST) scheme, based on the combined analysis of two recently proposed MLST approaches. Here, thirteen concatenated gene fragments were applied to a panel of T. cruzi reference strains encompassing all known genetic lineages. Concatenation of 13 fragments allowed assignment of all strains to the predicted Discrete Typing Units (DTUs), or near-clades, with the exception of one strain that was an outlier for TcV, due to apparent loss of heterozygosity in one fragment. Monophyly for all DTUs, along with robust bootstrap support, was restored when this fragment was subsequently excluded from the analysis. All possible combinations of loci were assessed against predefined criteria with the objective of selecting the most appropriate combination of between two and twelve fragments, for an optimized MLST scheme. The optimum combination consisted of 7 loci and discriminated between all reference strains in the panel, with the majority supported by robust bootstrap values. Additionally, a reduced panel of just 4 gene fragments displayed high bootstrap values for DTU assignment and discriminated 21 out of 25 genotypes. We propose that the seven-fragment MLST scheme could be used as a gold standard for T. cruzi typing, against which other typing approaches, particularly single locus approaches or systematic PCR assays based on amplicon size, could be compared. The single-celled parasite Trypanosoma cruzi occurs in mammals and insect vectors in the Americas. When transmitted to humans it causes Chagas disease (American trypanosomiasis) a major public health problem. T. cruzi is genetically diverse and currently split into six groups, known as TcI to TcVI. Multilocus sequence typing (MLST) is a method used for studying the population structure and diversity of pathogens and involves sequencing DNA of several different genes and comparing the sequences between isolates. Here, we assess 13 T. cruzi genes and select the best combination for diversity studies. Outputs reveal that a combination of 7 genes can be used for both lineage assignment and high resolution studies of genetic diversity, and a reduced combination of four loci for lineage assignment. Application of MLST for assigning field isolates of T. cruzi to genetic groups and for detailed investigation of diversity provides a valuable approach to understanding the taxonomy, population structure, genetics, ecology and epidemiology of this important human pathogen.

11 December 2014 in Expert Review of Vaccines
Verified
Journal Article
Closed access
FSFernando J Sánchez-Valdéz
Fernando J Sánchez-Valdéz
Cecilia Perez BrandanCecilia Perez Brandan
Cecilia Perez Brandan
AFArturo Ferreira
Arturo Ferreira
MBMiguel Ángel Basombrío
Miguel Ángel Basombrío
Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. This illness is now becoming global, mainly due to congenital transmission, and so far, there are no prophylactic or therapeutic vaccines available to either prevent or treat Chagas disease. Therefore, different approaches aimed at identifying new protective immunogens are urgently needed. Live vaccines are likely to be more efficient in inducing protection, but safety issues linked with their use have been raised. The development of improved protozoan genetic manipulation tools and genomic and biological information has helped to increase the safety of live vaccines. These advances have generated a renewed interest in the use of genetically attenuated parasites as vaccines against Chagas disease. This review discusses the protective capacity of genetically attenuated parasite vaccines and the challenges and perspectives for the development of an effective whole-parasite Chagas disease vaccine.

1 March 2011 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
NTNicolás Tomasini
Nicolás Tomasini
JLJuan Jose Lauthier
Juan Jose Lauthier
MRMaría M. Monje Rumi
María M. Monje Rumi
PRPaula G. Ragone
Paula G. Ragone
ADAnahí A. Alberti D’aMato
Anahí A. Alberti D’aMato
PDPatricio Diosque
Patricio Diosque

1 January 2019 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
AMAndrea Cecilia Mesias
Andrea Cecilia Mesias
NSNatalia Sasoni
Natalia Sasoni
DADiego G. Arias
Diego G. Arias
Cecilia Perez BrandanCecilia Perez Brandan
Cecilia Perez Brandan
OOOliver C.F. Orban
Oliver C.F. Orban
MZM. Paola Zago
M. Paola Zago